Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
143.63
+0.59 (0.41%)
Nov 12, 2024, 4:00 PM EST - Market closed
Glaukos Revenue
Glaukos had revenue of $96.67M in the quarter ending September 30, 2024, with 23.86% growth. This brings the company's revenue in the last twelve months to $360.35M, up 18.70% year-over-year. In the year 2023, Glaukos had annual revenue of $314.71M with 11.26% growth.
Revenue (ttm)
$360.35M
Revenue Growth
+18.70%
P/S Ratio
20.36
Revenue / Employee
$397,295
Employees
907
Market Cap
7.92B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 147.66B |
Henry Schein | 12.50B |
The Ensign Group | 4.11B |
Jazz Pharmaceuticals | 3.99B |
Bruker | 3.24B |
Chemed | 2.38B |
Halozyme Therapeutics | 947.36M |
Repligen | 602.35M |
GKOS News
- 5 days ago - Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
- 7 days ago - Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds - Benzinga
- 8 days ago - Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Glaukos Announces Third Quarter 2024 Financial Results - Business Wire
- 27 days ago - Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety - Business Wire
- 4 weeks ago - Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting - Business Wire
- 5 weeks ago - Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 - Business Wire
- 7 weeks ago - Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement - GlobeNewsWire